Physician profile
Michael A Raio
NPI 1568573780
$4,957.93
in general payments reported to CMS, 2019-2025
41 companies · $829 in 2025
The $829 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $280 · 2021: $711 · 2022: $758 · 2023: $880 · 2024: $1,258 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $808.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $538.83 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $442.01 | 2020-2025 | Verquvo, Belsomra, Gardasil 9 |
| Daiichi Sankyo INC. | $332.48 | 2019-2024 | Injectafer |
| Amgen INC. | $327.35 | 2021-2025 | Repatha, Evenity, Tepezza |
| Novo Nordisk INC | $308.60 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $171.20 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $152.58 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $152.54 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Pfizer INC. | $149.71 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $136.02 | 2020-2023 | Xarelto |
| Amarin Pharma, INC. | $132.42 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.19 | 2021-2025 | Xifaxan |
| Abbvie INC. | $100.74 | 2022-2025 | |
| Mannkind Corporation | $92.38 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.